Neurocrine Biosci…
USUSDNeurocrine Biosciences Inc (US:NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- neurocrine.com
- Investor relations
- neurocrine.com/investors/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- San Diego, United States
- Management
- Latest reports
- annual 2026 2026 Proxy Statement
- Employees
- 2 500
- Founded
- 1992
- IPO
- 1996-05-23
- Shares outstanding
- Free float
- 100.37 M
- Market cap
- 14.79 B USD
- Insiders
- 1.06%
- Institutions
- 102.84%
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Legal form
- XTIQ
- ISIN
- US64125C1099
- LEI
- 549300FECER0XBN49756
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- 24.6
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- 6.74 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 4.3314.2
- Graham numberGraham number — the highest price Benjamin Graham considered reasonable for a defensive investor: √(22.5 × EPS × tangible book value per share), where 22.5 = P/E 15 × P/B 1.5. A price below it (green) passes both of his limits at once. Not calculated with a loss or negative tangible equity.
- 42.16 USD price 294% above
- ROEROE (return on equity) is net income over the last 12 months divided by average shareholders' equity over those 12 months. It shows how much profit the company earns on every 100 dollars of capital. Consistently above 15% is a sign of a strong business, but a high ROE can also come from heavy debt or small equity after buybacks. One-off gains (sale of a business, revaluation, tax benefit) are excluded; «!» explains why the value differs from the reported one or is unreliable. Companies with negative equity have no ROE.
- 20.4%
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- 1.04 B USD
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
- ?
- Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Exchanges and tickers
Candles
Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.
P/E
The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.
For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.
My position
Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Blackrock Inc. | 13.49% | 13.71 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 6.29% | 6.4 M | 2026-06-30 |
| Dodge & Cox Inc. | 5.49% | 5.58 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.89% | 4.97 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.47% | 4.55 M | 2026-06-30 |
| State Street Corporation | 4.31% | 4.39 M | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.9% | 3.96 M | 2026-06-30 |
| AQR Capital Management,… | 3.76% | 3.82 M | 2026-06-30 |
| iShares Trust-iShares Co… | 3.46% | 3.52 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.14% | 3.19 M | 2026-06-30 |
| Renaissance Technologies… | 2.3% | 2.34 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.27% | 2.3 M | 2026-06-30 |
| Geode Capital Management… | 2.1% | 2.14 M | 2026-06-30 |
| Two Sigma Investments, L… | 2.04% | 2.08 M | 2026-06-30 |
| J.P. Morgan Mutual Fd. I… | 1.34% | 1.36 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 1.33 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.13% | 1.15 M | 2026-06-30 |
| JPMorgan Trust II-JPMorg… | 1.1% | 1.12 M | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.73% | 739 670 | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.72% | 735 342 | 2026-08-31 |
| GORMAN KEVIN CHARLES (Di… | ≈0.51% | 517 797 | 2026-09-11 |
| GANO KYLE W (Chief Execu… | ≈0.15% | 154 728 | 2026-09-11 |
| LYONS GARY A (Director) | ≈0.12% | 122 141 | 2026-05-21 |
| BENEVICH ERIC S. (Office… | ≈0.07% | 67 297 | 2026-09-11 |
| LIPPOLDT DARIN M (Office… | ≈0.06% | 56 793 | 2026-09-11 |
| RASTETTER WILLIAM H (Dir… | ≈0.04% | 43 678 | 2026-05-21 |
| ABERNETHY MATTHEW C (Chi… | ≈0.04% | 42 808 | 2026-09-14 |
| POPS RICHARD F (Director… | ≈0.04% | 37 798 | 2026-05-21 |
| ROBERTS EIRY WYN (Office… | ≈0.04% | 35 640 | 2025-02-14 |
| COOKE JULIE SMITH (Offic… | ≈0.02% | 24 025 | 2026-09-11 |
